AMCHAM convened a closed-door virtual interaction between members of the Pharmaceuticals Committee and officials from the United States Patent and Trademark Office (USPTO) on December 18th, to discuss key intellectual property (IP) issues impacting U.S. pharmaceutical companies operating in India. The discussion focused on the importance of a predictable and innovation-friendly IP ecosystem to support R&D investments and timely patient access to advanced therapies. Members shared industry perspectives on challenges related to patent examination timelines, pre-grant oppositions, regulatory data protection, enforcement against counterfeiting, compulsory licensing, and the absence of patent linkage in India. Participants also highlighted ongoing regulatory and market access concerns, including delays in new drug approvals, lack of a clear framework for data exclusivity, and the need for stronger and more coordinated IP enforcement mechanisms. The interaction acknowledged positive steps taken by the Government of India, including increased stakeholder consultations, digitization of IP processes, and capacity-building initiatives. AMCHAM emphasized the need for continued dialogue and alignment with global best practices to strengthen India’s IP framework. AMCHAM looks forward to continued engagement with USPTO and Indian stakeholders to support a balanced IP regime that promotes innovation, investment, and public health objectives, while reinforcing India’s position as a global life sciences hub.